Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE:FRX) announced results from additional analyses of their Phase 2b study assessing the safety and efficacy of the novel, first-in-class agent linaclotide in 419 patients with irritable bowel syndrome with constipation (IBS-C). Previous analyses of these data indicated that once-daily oral dosing with linaclotide, across a range of doses, significantly improved abdominal symptoms, bowel habits, and global assessments over the 12-week treatment period. These additional analyses demonstrated that patients treated with linaclotide experienced a statistically significant improvement in abdominal symptoms, bowel habits, and global...

Want to see the full article?

• Purchase this article for only $3.00